AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04304040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized monoclonal antibody MIL62 injection
Description: Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
Study NCT00517556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCOCP
Description: (CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
Study NCT00517556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional OCP
Description: (traditional OCP) (21 active days/7 inactive days) treatment regimen
Study NCT01844856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Study NCT01844856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study NCT04382586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Study NCT04382586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Study NCT04382586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match zanubrutinib
Study NCT04532294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB DXP593
Description: Administered intravenously (IV) as specified in the treatment arm
Study NCT04532294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP593
Study NCT01636336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Study NCT01636336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
Study NCT04000607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APTURE transcatheter shunt
Description: Transcatheter treatment of symptomatic left heart failure patients
Study NCT00420927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Study NCT03032146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
Study NCT04383795 — intervention group
Intervention type: DRUG
Intervention: Antithyroid Drug
Description: Administration of antithyroid Drug for 6 months
Study NCT00320411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 1500mg QD
Study NCT01947205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Study NCT01947205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol
Study NCT01947205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suction curettage
Study NCT03136172 — intervention group
Intervention type: DEVICE
Intervention: NIRS (near Infra-red spectroscopy)
Description: 1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)
Study NCT01947205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without drug
Study NCT02332850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium-vitamin D supplement
Description: daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo
Study NCT04283773 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267)
Description: Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).
Study NCT02332850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT02332850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT03085420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
Study NCT00700960 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
Study NCT00449774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine IR tablets
Description: Lamotrigine IR tablets will be available in dose strength of 200 mg.
Study NCT00449774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine ODT tablets
Description: Lamotrigine ODT tablets will be available in dose strength of 200 mg.
Study NCT02902198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tap water 200ml
Study NCT02902198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 25g Glucose in 200ml tap water
Study NCT02902198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Monosodium glutamate
Description: 1g monosodium glutamate in 200ml tap water
Study NCT02902198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: 17mg quinine in 200ml tap water
Study NCT05145530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective anterior cervical discectomy and fusion (ACDF)
Description: selective anterior cervical discectomy and fusion (ACDF)
Study NCT05145530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNRB+ selective anterior cervical discectomy and fusion (ACDF)
Description: US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
Study NCT03764501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Image fusion system
Description: Image fusion system for the 3D preoperative planning
Study NCT00861276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray Nicotine Substitute (Experimental)
Description: During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
Study NCT00861276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Spray Nicotine Substitute (ad libitum)
Description: In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
Study NCT00977249 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: support and visits
Description: visits at weeks 0,2,4,6,9 and 12 and 12 months
Study NCT00977249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support and visits
Description: visits at weeks 0,2,4,6,9 and 12 and 12 months
Study NCT00977249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Study NCT00977249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04325217 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Capsules
Study NCT01185600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Washed RBC
Description: There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
Study NCT04283773 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Ki67 antibody (DAKO) for malignant cases only
Description: Treatment of slides that cut from paraffin embedded blocks related to malignant case group by immunohistochemical method by Ki67 antibody.
Study NCT00693563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Telephone Intervention
Description: Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
Study NCT06049628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA 11+ exercise program
Description: FIFA 11+ program; It consists of simple, easily remembered, and time-consuming, sport-specific exercises underlying fair play. The F 11+ consisted of 3 parts: the first part consisted of running exercises (part 1); the second part included six exercises, which were made up of three levels of difficulty and aimed at enhancing balance, strength, muscle control, and core stability (part 2). The final and the third part covered advanced running exercises (part 3) .
Study NCT06049628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine program
Description: This program consists of jogging, and stretching exercises.
Study NCT03042494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Isocaloric food without the test prebiotic.
Study NCT03042494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
Study NCT02482415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-educational
Study NCT01097733 — intervention group
Intervention type: OTHER
Intervention: Randomization of Pre-knowledge of CT coronary venography
Study NCT04990999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Root Extraction
Description: a 1-cm long vestibular access incision was cut, 3-4 mm apical to the mucogingival junction of the involved tooth, then pushing the vestibular pouch in an incisal direction exposing the apical root area, and allowing direct undisturbed access to the root surface
Study NCT04990999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic extractions using periotomes followed by conventional forceps
Description: a sulcular releasing incision suing a micro scalpel was made to detach the surrounding tissues, followed by applying the periotome interproximally into the PDL space, widening the attached periodontal ligaments space.
Study NCT01844856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study NCT01844856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV to maintain the blind.
Study NCT04171635 — intervention group
Intervention type: RADIATION
Intervention: Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)
Description: Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
Study NCT04171635 — intervention group
Intervention type: RADIATION
Intervention: R2* Magnetic Resonance Imaging (MRI)
Description: Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
Study NCT03869385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albutein® 200 g/L or Plasbumin® 20
Description: The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
Study NCT02406469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral consumption milk Tetra Pak
Description: Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
Study NCT02406469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral consumption milk Tetra Pak
Description: Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
Study NCT01185600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unwashed RBC
Description: There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
Study NCT04003259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle management programme
Description: The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
Study NCT03483051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
Study NCT03483051 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Potassium Chloride
Description: Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
Study NCT00890591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Description: olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
Study NCT01543282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)
Description: Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
Study NCT01543282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)
Description: Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
Study NCT02907216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Squarekids
Description: Three doses administered subcutaneously in the upper arm or thigh
Study NCT02907216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Squarekids
Description: Three doses administered subcutaneously in the upper arm or thigh
Study NCT02907216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two doses administered orally
Study NCT02907216 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix
Description: Two doses administered orally
Study NCT03935867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C-PROFET
Description: An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
Study NCT00983333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Time to Talk CARDIO website
Description: This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
Study NCT01301066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD
Study NCT01301066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg QD
Study NCT03232021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule administered 1 hour prior to the surgical operation
Study NCT03232021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 75mg
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
Study NCT00540657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX282-B
Description: 250mg capsule, twice daily, 13 weeks
Study NCT00540657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, twice daily, 13 weeks
Study NCT02242136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FORNET
Study NCT03232021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 150 mg
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Study NCT01624454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laxabon
Description: 4 l PEG solution split dose cleansing
Study NCT01624454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CitraFleet
Description: Small volume osmotic bowelcleansing
Study NCT03740711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial venting
Description: The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.